Nucleobases Found on Asteroid Ryugu, Glucose-to-Gluconate Diabetes Implant, KCL-286 Targets Upstream of Amyloid, Lacosamide for Knee Arthritis, Microplastic ROS Generation, and Endometrial Cancer Swab Test

Broadcast from KSQD, Santa Cruz on 11-05-2026:

Japan's Hayabusa2 mission returned 5 grams of pristine samples from asteroid Ryugu in contamination-proof conditions, and analysis found all five of the nucleobases that form the letters of DNA and RNA (pyrimidines and purines)—replicating a 2025 NASA result and strengthening the case that genetic-material building blocks may originate in space.

A Swiss research group developed a graphite-felt implant studded with gold nanoclusters coated in platinum particles that catalytically oxidizes glucose to gluconate, a waste product eliminated in urine rather than stored as fat. Wirelessly powered through a continuous glucose monitor and smartphone, the device activates only when blood sugar rises too high. Experimental diabetic mice lost weight and their blood sugar. This new invention addresses the excess-energy problem that insulin alone leaves untouched.

King's College London researchers identified KCL-286,as a promising Alzheimer's candidate that works upstream of the beta-amyloid and tau deposits that dominated three decades of failed drug development. KCL-286 was originally developed for spinal cord injury and has already passed phase-one human safety trials. The orally bioavailable small molecule activates a retinoic acid pathway protein that repairs DNA double-strand breaks and reduces inflammation—the actual early drivers of non-hereditary Alzheimer's.

Dr. Dawn riffs on "type 3 diabetes," the functional medicine framing for high-glucose brain inflammation driving dementia. She emphasizes the disturbing statistic that poor blood sugar control epidemiologically subtracts about 10 years from dementia-free lifespan.

Yale researchers found the approved epilepsy drug lacosamide blocks a sodium channel that is unusually active in osteoarthritic chondrocytes, where it drives both pain signaling and cartilage destruction. Injected monthly in a temperature-responsive collagen type 2 hydrogel that gels at body heat to keep the drug in the joint, lacosamide reduced pain, encouraged cartilage-building proteins, and suppressed tissue breakdown, greatly outperforming daily oral dosing.

A caller asks about newly prescribed alendronate and oyster-shell calcium for osteoporosis; Dr. Dawn explains alendronate cross-links bone calcium so osteoclasts can't easily break it down, slowing fractures—but also slowing dental implant and joint-replacement healing, with rare atypical femur fractures after years of use (drug holida